Current concepts on pathogenesis and biology of metastatic osteosarcoma tumors;Aktualne pogla dyna patoge neze ibiolo gie prze rzu to wych gu zów kost nia ko mie sa ka

Ortopedia Traumatologia Rehabilitacja

Volumn 13, Issue 6, 2011, Pages 537-545

  Poletajew, Sławomir ^a   Fus, Łukasz ^a   Wasiutyński, Aleksander ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Bone neoplasms; Neoplasm metastasis; Neoplastic stem cells; Neovascularization; Osteosarcoma

Indexed keywords

ANIMAL; BONE TUMOR; CANCER STEM CELL; DISEASE COURSE; EXTRACELLULAR MATRIX; HUMAN; METABOLISM; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); OSTEOSARCOMA; REVIEW; TUMOR EMBOLISM;

ANIMALS; BONE NEOPLASMS; DISEASE PROGRESSION; EXTRACELLULAR MATRIX; HUMANS; NEOPLASTIC CELLS, CIRCULATING; NEOPLASTIC STEM CELLS; NEOVASCULARIZATION, PATHOLOGIC; OSTEOSARCOMA;

EID: 84856326501     PISSN: 15093492     EISSN: None     Source Type: Journal    
DOI: 10.5604/15093492.971038     Document Type: Article

References (46)

1. Kempf-Bielack B, Bielack SS, Jürgens H, et al. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol. 2005;23(3):559-68
2. Bruland ØS, Høifødt H, Hall KS, Smeland S, Fodstad Ø. Bone marrow micrometastases studied by an immunomagnetic isolation procedure in extremity localized non-metastatic osteosarcoma patients. Cancer Treat Res. 2009;152:509-15
3. Paget S. The distribution of secondary growths in cancer of the breast. Cancer Metastasis Rev. 1989;8(2):98-101
4. Ewing J: Neoplastic Diseases. A Treatise on Tumors. Philadelphia, PA, Saunders 1928
5. Bjørnland K, Flatmark K, Pettersen S, Aaasen AO, Fodstad O, Maelandsmo GM. Matrix metalloproteinases participate in osteosarcoma invasion. J Surg Res. 2005;127(2):151-6
6. Korpi JT, Hagström J, Lehtonen N, et al. Expression of matrix metalloproteinases-2, -8, -13, -26, and tissue inhibitors of metalloproteinase-1 in human osteosarcoma. Surg Oncol. 2011;20(1):e18-22
7. Uchibori M, Nishida Y, Nagasaka T, Yamada Y, Nakanishi K, Ishiguro N. Increased expression of membrane-type matrix metalloproteinase-1 is correlated with poor prognosis in patients with osteosarcoma. Int J Oncol. 2006;28(1):33-42
8. Kang HG, Kim HS, Kim KJ, et al. RECK expression in osteosarcoma: correlation with matrix metalloproteinases activation and tumor invasiveness. J Orthop Res. 2007;25(5):696-702
9. Ferrari C, Benassi S, Ponticelli F, et al. Role of MMP-9 and its tissue inhibitor TIMP-1 in human osteosarcoma: findings in 42 patients followed for 1-16 years. Acta Orthop Scand. 2004;75(4):487-91
10. Xu J, Wu S, Shi X. Expression of matrix metalloproteinase regulator, RECK, and its clinical significance in osteosarcoma. J Orthop Res. 2010;28(12):1621-5
11. Martin TA, Harrison G, Mansel RE, Jiang WG. The role of the CD44/ezrin complex in cancer metastasis. Crit Rev Oncol Hematol. 2003;46(2):165-86
12. Wan X, Mendoza A, Khanna C, Helman LJ. Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteo sarcoma. Cancer Res. 2005;65(6):2406-11
13. Khanna C, Wan X, Bose S, et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med. 2004;10(2):182-6
14. Di Cristofano C, Leopizzi M, Miraglia A, et al. Phosphorylated ezrin is located in the nucleus of the osteosarcoma cell. Mod Pathol. 2010;23(7):1012-20
15. Ogino W, Takeshima Y, Mori T, et al. High level of ezrin mRNA expression in an osteosarcoma biopsy sample with lung metastasis. J Pediatr Hematol Oncol. 2007;29(7):435-9
16. Dang CV, Semenza GL. Oncogenic alterations of metabolism. Trends Biochem Sci. 1999;24(2):68-72
17. Kim JW, Gao P, Dang CV. Effects of hypoxia on tumor metabolism. Cancer Metastasis Rev. 2007;26(2):291-8
18. Knowles HJ, Schaefer KL, Dirksen U, Athanasou NA. Hypoxia and hypoglycaemia in Ewing's sarcoma and osteosarcoma: regulation and phenotypic effects of Hypoxia-Inducible Factor. BMC Cancer. 2010;10:372
19. Mizobuchi H, García-Castellano JM, Philip S, Healey JH, Gorlick R. Hypoxia markers in human osteosarcoma: an exploratory study. Clin Orthop Relat Res. 2008;466(9):2052-9
20. Yang QC, Zeng BF, Dong Y, Shi ZM, Jiang ZM, Huang J. Overexpression of hypoxia-inducible factor-1alpha in human osteosarcoma: correlation with clinicopathological parameters and survival outcome. Jpn J Clin Oncol. 2007;37(2):127-34
21. Szala S. Angiogenesis and immune suppression: yin and yang of tumor progression? Postepy Hig Med Dosw. 2009;63:598-612
22. Kaya M, Wada T, Akatsuka T, et al. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res. 2000;6(2):572-7
23. Lee YH, Tokunaga T, Oshika Y, et al. Cell-retained isoforms of vascular endothelial growth factor (VEGF) are correlated with poor prognosis in osteosarcoma. Eur J Cancer. 1999;35(7):1089-93
24. Oda Y, Yamamoto H, Tamiya S, et al. CXCR4 and VEGF expression in the primary site and the metastatic site of human osteosarcoma: analysis within a group of patients, all of whom developed lung metastasis. Mod Pathol. 2006;19(5):738-45
25. Yin D, Jia T, Gong W, et al. VEGF blockade decelerates the growth of a murine experimental osteosarcoma. Int J Oncol. 2008;33(2):253-9
26. Wang D, Chen L, Gao F. Correlation of tumor microvessel density with prognosis in osteogenic sarcoma. Zhonghua Bing Li Xue Za Zhi. 1997;26(5):266-9
27. Mantadakis E, Kim G, Reisch J, et al. Lack of prognostic significance of intratumoral angiogenesis in nonmetastatic osteosarcoma. J Pediatr Hematol Oncol. 2001;23(5):286-9
28. Ek ET, Ojaimi J, Kitagawa Y, Choong PF. Does the degree of intratumoural microvessel density and VEGF expression have prognostic significance in osteosarcoma? Oncol Rep. 2006;16(1):17-23
29. Kreuter M, Bieker R, Bielack SS, et al. Prognostic relevance of increased angiogenesis in osteosarcoma. Clin Cancer Res. 2004;10(24):8531-7
30. Ben-Baruch A. Site-specific metastasis formation: chemokines as regulators of tumor cell adhesion, motility and invasion. Cell Adh Migr. 2009;3(4):328-33
31. Kim SY, Lee CH, Midura BV, et al. Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. Clin Exp Metastasis. 2008;25(3):201-11
32. Perissinotto E, Cavalloni G, Leone F, et al. Involvement of chemokine receptor 4/stromal cell-derived factor 1 system during osteosarcoma tumor progression. Clin Cancer Res. 2005;11(2 Pt 1):490-7
33. von Luettichau I, Segerer S, Wechselberger A, et al. A complex pattern of chemokine receptor expression is seen in osteosarcoma. BMC Cancer. 2008;8:23
34. Laverdiere C, Hoang BH, Yang R, et al. Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma. Clin Cancer Res. 2005;11(7):2561-7
35. Baldini N, Scotlandi K, Serra M, et al. P-glycoprotein expression in osteosarcoma: a basis for risk-adapted adjuvant chemotherapy. J Orthop Res. 1999;17(5):629-32
36. Ferrari S, Bertoni F, Zanella L, et al. Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma. Cancer. 2004;100(9):1936-42
37. Serra M, Scotlandi K, Reverter-Branchat G, et al. Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities. J Clin Oncol. 2003;21(3):536-42
38. Pakos EE, Ioannidis JP. The association of P-glycoprotein with response to chemotherapy and clinical outcome in patients with osteosarcoma. A meta-analysis. Cancer. 2003;98(3):581-9
39. Gorlick R, Anderson P, Andrulis I, et al. Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary. Clin Cancer Res. 2003;9(15):5442-53
40. Scotlandi K, Manara MC, Serra M, et al. The expression of P-glycoprotein is causally related to a less aggressive phenotype in human osteosarcoma cells. Oncogene. 1999;18(3):739-46
41. Gil J, Stembalska A, Pesz KA, Sasiadek MM. Cancer stem cells: the theory and perspectives in cancer therapy. J Appl Genet. 2008;49(2):193-9
42. Siclari VA, Qin L. Targeting the osteosarcoma cancer stem cell. J Orthop Surg Res. 2010;5:78
43. Wang L, Park P, Lin CY. Characterization of stem cell attributes in human osteosarcoma cell lines. Cancer Biol Ther. 2009;8(6):543-552
44. Gibbs CP, Kukekov VG, Reith JD, et al. Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia. 2005;7(11):967-76
45. Lopes A, Neves SR, do Carmo A, Paiva AA, Botelho M, Gomes CM. Identification of cancer stem-like cells in osteosarcoma and their implications in response to chemotherapy. BMC Proceedings 2010, 4(Suppl 2):P41
46. Mohseny AB, Szuhai K, Romeo S, et al. Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2. J Pathol. 2009;219(3):294-305